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CASE REPORT
Recurrent amebic liver abscesses over a 
16‑year period: a case report
D. Creemers‑Schild1,2, P. J. J. van Genderen1, L. G. Visser2, J. J. van Hellemond3* and P. J. Wismans1
Abstract 
Background: Amebic liver abscess is a rare disease in high‑income countries. Recurrence of amebic liver abscess is 
even rarer with only a few previous reports. Here we present a patient who developed three subsequent amebic liver 
abscesses over a sixteen‑year period.
Case presentation: A Caucasian male developed recurrent amebic liver abscesses, when aged 23, 27 and 39 years. 
Only on the first occasion did this coincide with a recent visit to the tropics. The patient received adequate treatment 
during each episode. Possible explanations are persistent asymptomatic carrier state, cysts passage in his family, re‑
infection or chance.
Conclusion: We describe the unusual case of a healthy male who developed recurrent amebic liver abscesses over a 
long period despite adequate treatment. Possible pathophysiological explanations are explored.
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Background
Intestinal amebiasis and amebic liver abscess, caused by 
the protozoan Entamoeba histolytica, are rarely reported 
from high-income countries. It is mostly encountered as 
an imported disease from regions with poor sanitation 
levels. Infection occurs through ingestion of E. histol-
ytica cysts in contaminated food or water. Most infec-
tions remain asymptomatic while approximately 10  % 
of patients develop invasive disease and less than 1 % of 
the infections result in liver abscess [1]. Recurrence of 
amebic liver abscess after appropriate treatment with the 
combination of a nitroimidazole derivate with a lumi-
nal agent is rare with only a few previous reports [2–4]. 
The majority of those recurrences could be explained by 
failure to administer an adequate luminal agent [5–8]. 
We report an extraordinary case of a Caucasian (Dutch) 
male patient, who developed amebic liver abscesses three 
times over a period of 16 years, despite adequate combi-
nation treatment on each occasion.
Case presentation
A previously healthy 23-year old, Caucasian man was 
admitted for the first time 19 years ago (1997), at the age 
of 23 with a 4-week history of upper right abdominal 
pain, loose stools and fever. Three months previously he 
had made a 5-week trip through Indonesia, Thailand and 
Malaysia. Laboratory testing revealed elevated inflam-
matory parameters and a slightly increased gamma-glu-
tamyltransferase (Table  1). Ultrasound of the abdomen 
demonstrated a vaguely defined area in the right liver 
lobe compatible with an abscess and Entamoeba spp. 
cysts were detected in a stool sample, supporting the 
diagnosis of an amebic liver abscess. On admission no 
specific antibodies against E. histolytica were detectable 
using an ELISA method. The liver abscess was not aspi-
rated. The patient was treated with metronidazole fol-
lowed by diloxanide furoate with good clinical response. 
Serology for E. histolytica was positive one month later. 
Six months later, stool examination by microscopy for 
cysts was negative.
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Four years later (2001) the patient was admitted with 
a 10 cm large abscess high in the liver with a 5-day his-
tory of spiking fever and malaise. Since 1997 he had 
travelled once to Nepal and Bangladesh in 1999. The 
patient was again diagnosed with an amebic liver abscess, 
which was supported by positive serology results. Treat-
ment was initiated with metronidazole. However, fever 
persisted and after 5  days percutaneous drainage of the 
abscess was performed. In the aspirate no trophozoites 
of E. histolytica were found and the bacterial cultures 
remained negative. The recovery hereupon was unevent-
ful and a 10-day course of metronidazole was followed 
by diloxanide furoate for 10  days. Ultrasound of the 
liver demonstrated complete resolution of the abscess 
6 months later.
Finally, three years ago—with a twelve year interval 
(2013)—the patient was admitted for the third time with a 
5-day history of spiking fever and upper abdominal pain. 
Table 1 Clinical characteristics of the 3 episodes of amebic liver abscesses
CT computed tomography, PCR polymerase chain reaction, ND not determined
a Results from samples collected June 9, 2013 and September 4, 2013, respectively (cut off <1:40)
b One week after presentation during the 3rd episode the patient was readmitted and C‑reactive protein decreased to 46 mg/L, aspartate aminotransferase increased 
to and 42 U/L and gamma‑glutamyltransferase increased to 129 U/L, the size of the abscess increased to 5 × 7 cm
c State of the art treatment on all occasions: nitroimidazole derivate followed by a luminal agent
1st episode (1997) 2nd episode (2001) 3rd episode (2013)
Age (years) 23 27 39
Symptoms 4 weeks fever, sweating, upper right 
abdominal pain
5 days spiking fever, malaise 5 days spiking fever, sweating, upper 
abdominal pain
Physical examination Temperature 38.4, upper right 
abdominal tenderness
No abnormalities temperature 37.1, upper abdominal 
tenderness
Laboratory tests (reference range)
 Hemoglobin mmol/L (8.5–11.0) 7,2 8,3 8,7
 Leucocytes × 109/L (4.0–10.0) 11 19,7 24,4
 C‑reactive protein mg/L (0–5) ND 276 339b
 Erythrocyte sedimentation rate 
mm/hr (<15)
94 63 74
 Bilirubin total µmol/L (0–17) 8 29 15
 Aspartate aminotransferase U/L 
(0–35)
23 19 28b
 Alanine aminotransferase U/L 
(0–45)
69 46 23
 Alkaline phosphatase U/L (0–390) ND 107 99
 Lactate dehydrogenase U/L 
(0–248)
244 288 160
 Gamma‑glutamyltransferase U/L 
(0–55)
190 58 63b
 Creatinine µmol/L (64–104) ND 101 86
Radiology Liver abscess in the right lobe, size 
6 × 5 cm (ultrasound)
Abscess high in the liver, size 10 cm 
(CT)
Liver abscess in the right lobe, 
size 4.9 × 4.5 cm with satellite 
abscesses (CT)b
Additional tests
 Stool microscopy Entamoeba spp. Cysts Negative Entamoeba spp. cysts and tropho‑
zoites
 Stool PCR E. histolytica ND ND positive
 Serology for amebiasis <1:40, 1 month later 1:320 1:320 1:640 and 1:640a
 Abscess fluid ND Culture negative, no amebic 
trophozoites
ND
Treatment Metronidazole 750 mg tid 7 days Metronidazole 750 mg tid 10 days Metronidazole 750 mg tid 10 days
Diloxanide furoate 500 mg tid 
10 days
Diloxanide furoate 500 mg tid 
10 days
Paromomycin 500 mg tid 10 days
Aspiration and drainage liver 
abscess
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Two years earlier, in 2011, the patient had been in Thai-
land for one week and had made short trips to China (in 
2006, 2009 and 2012). Laboratory examination revealed 
increased levels of inflammation markers and computed 
tomography (CT) showed an abscess of 5 cm in the right 
liver lobe with small satellite abscesses. For the third time 
the diagnosis of amebic liver abscess was made, based 
on positive serology results and the detection of E. his-
tolytica in a stool sample by polymerase chain reaction 
(PCR). Treatment was started with metronidazole. Ini-
tially the patient responded well and was discharged on 
day 5. After 10 days of metronidazole, paromomycin was 
started. One week after discharge, the patient was read-
mitted with persistent low-grade fever and abdominal 
pain. C-reactive protein concentration had decreased 
(46 mg/L), but slightly increased levels of aspartate ami-
notransferase (42  U/L) and gamma-glutamyltransferase 
(129 U/L) were noted. A new CT-scan revealed a subtle 
increase in the size of the abscess with subcapsular exten-
sion (Fig. 1). Percutaneous drainage was deferred because 
the clinical condition improved. The patient subsequently 
made an uncomplicated recovery and has remained in 
excellent condition to date. There were no indications of 
immune deficiencies. Normal amounts of T- and B-cells, 
immunoglobulins and complement factors were found 
(Table  2). In addition a human immunodeficiency virus 
(HIV) test was negative.
Stool samples of the patient’s wife, who accompanied 
him from the first amebic abscess episode onwards, and 
their 2 children were investigated for E. histolytica. The 
wife tested positive for E. histolytica by PCR examination 
of the stool, but E. histolytica serology was negative. She 
was treated with paromomycin 500 mg tid for 10 days.
Discussion
Our patient suffered from recurrent amebic liver 
abscesses on three separate occasions over a period of 
16 years. Each time the diagnosis of amebic liver abscess 
was based on the clinical presentation, ultrasound or 
CT imaging and positive E. histolytica serology. The first 
and third episode Entamoeba spp. cysts were detected 
in stool samples. The abscess was aspirated only in the 
second episode; no trophozoites of E. histolytica were 
detected. The material was obtained 5  days after initia-
tion of therapy, which probably accounts for the nega-
tive result of microscopy. The diagnosis of amebic liver 
abscess was further supported in each episode by clinical 
response after appropriate treatment.
Only a small proportion of E. histolytica-infected indi-
viduals develop invasive disease, whereas the majority 
of individuals carry the parasite within the gut without 
clinical symptoms [1]. Previous studies have indicated 
that both cell-mediated immunity and macrophage-
mediated effector mechanisms are involved in host 
resistance to E. histolytica infection [9]. Neutrophils acti-
vated by interferon-γ (IFN-γ), tumour necrosis factor-α 
(TNF-α), or lipopolysaccharides (LPS) have amebicidal 
activity in  vitro by releasing reactive oxygen species. 
Macrophages are also amebicidal after stimulation with 
IFN-γ or TNF-α. Important for the host defence against 
E. histolytica is a proper functioning of natural killer T 
cells (NKT cells) for the production of sufficient IFN-γ 
and nitric oxide, which induces the amebicidal activity of 
macrophages [9–11]. Moran et al. suggested that defects 
in production of reactive oxygen species are a risk factor 
Fig. 1 Upper abdominal computed tomography scan revealing an 
abscess of 7 cm in the right liver lobe with a small margin of liver tis‑
sue to the right hemidiaphragm and subcapsular extension
Table 2 Laboratory evaluation of  the immune system 
of the patient
Variable Reference range adults Results
B‑cells (×109/L) 0.10–0.40 0.27
T‑cells (×109/L) 0.70–1.90 1.50
CD4 (×109/L) 0.40–1.30 0.90
CD8 (×109/L) 0.20–0.70 0.56
NK‑cells (×109/L) 0.10–0.40 0.29
IgG (g/L) 7.00–16.00 11.10
IgG1 (g/L) 4.90–11.40 9.25
IgG2 (g/L) 1.50–6.40 2.60
IgG3 (g/L) 0.20–1.10 0.51
IgG4 (g/L) 0.08–1.40 0.55
IgA (g/L) 0.76–3.91 2.33
IgM (g/L) 0.45–2.30 1.46
C3 (g/L) 0.90–1.80 1.11
C4 (g/L) 0.10–0.40 0.20
C1Q (g/L) 0.05–0.25 0.24
M‑protein negative
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for recurrence of amebic liver abscess [12]. There is also 
a protective role for lectin signalling and specific human 
leukocyte antigen (HLA) II alleles. A study of children in 
Bangladesh suggested a potential protective association 
with the HLA class II allele DQB1*0601 and the hete-
rozygous haplotype DQB1*0601/DRB1*1501 for invasive 
amebiasis [13].
There is no evidence of immune deficiencies in our 
patient, as the absolute number of NKT cells and other 
immune cells was within the normal range with an other-
wise uneventful medical history.
In contrast to amebic colitis, amebic liver abscess 
occurs more often in adult males. It is 10 times as com-
mon in men as in women and is a rare disease in chil-
dren [1, 14]. Lotter et al. investigated in a mouse model 
for amebic liver abscess the role of female and male sex-
ual hormones. Removal of testosterone by orchiectomy 
reduced the size of abscesses in male mice, while substi-
tution of testosterone in female mice increased the size 
of amebic liver abscesses. This may be attributable to the 
inhibitory effect of testosterone on the IFN-γ production 
by NKT cells [15].
There are several possible explanations for the recur-
rence of amebic liver abscesses in this patient. The 
patient had travelled frequently to Asia, and therefore 
he may have simply been re-infected during his travels. 
Alternatively, recurrent disease may have occurred due 
to transmission of cysts between household members. 
Transmission of E. histolytica within households has 
been reported earlier [16]. The patient’s wife tested posi-
tive for E. histolytica cysts in the stool when investigated 
after her husband’s third episode. After 2002 she had 
travelled annually to China (Beijing) and had accompa-
nied her husband during travel to Thailand and Nepal. A 
repeated infection from household members could have 
been supported by genotyping the strain(s) by means of 
PCR-fingerprinting [17]. Unfortunately, no material from 
past episodes was available to test this hypothesis. Per-
sistent asymptomatic carrier state appears to be highly 
unlikely since the patient was treated appropriately for 
persisting intraluminal cysts on all occasions. In addition, 
the intervals would be exceptionally long for recurrences 
resulting from inadequate treatment which usually occur 
within months, not years. On the other hand, Blessmann 
et  al. showed that diloxanide furoate was less effective 
than paromomycin in eradicating E. histolytica in asymp-
tomatic cyst carriers [18]. Some form of immune dys-
function or genetic susceptibility could also have played 
a role, but this possibility seems unlikely. Obviously all 
speculation on the mechanism(s) involved remains hypo-
thetical and this remarkable patient history may ulti-
mately simply have been a matter of chance.
Of note in this case is the decision during the third epi-
sode to continue conservative treatment without drain-
age. In a recent Cochrane review there was no benefit for 
drainage in addition to metronidazole in case of uncom-
plicated amebic liver abscess [19]. Aspiration should 
be considered for patients with either a large left-lobe 
abscesses, a lack of clinical response within 5 days and in 
case of uncertainty about the diagnosis [1]. Our patient 
had a right lobe abscess of 7 cm—with a suspicion of sub-
capsular expansion - but with a clear margin to the right 
pleural cavity (Fig.  1). His clinical condition improved 
during metronidazole treatment, illustrated by the dis-
appearance of the spiking fever and declining C-reactive 
protein levels (339–46 in 2 weeks).
Conclusion
We present the unusual case of a healthy Dutch male 
with recurrent amebic liver abscesses on three separate 
occasions over a period of 16  years despite adequate 
treatment. While the exact nature of the underlying 
pathophysiological mechanism(s) will remain obscure, 
we explored some of the possibilities such as cysts from 
an asymptomatic close contact or an as yet unidentified 
immune deficiency in the host. Our observation serves 
as a welcome reminder of the unpredictable course of 
amebiasis even in the absence of recent travel to tropical 
regions.
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